Although the absolute risks were low, the findings published in The BMJ suggest that "migraine should be considered a potent and persistent risk factor for most cardiovascular diseases in both men and women."
Around one billion people worldwide are affected by migraine, researchers said.
It has considerable impact on quality of life and imposes a substantial burden on society, they said.
Researchers from Aarhus University Hospital in Denmark and Stanford University, US collected patient data from the Danish National Patient Registry over a 19 year period, from 1995 to 2013.
For each person with migraine, they matched 10 people of the same age and gender who were migraine free.
The average age for migraine diagnosis was 35 years, and 71 per cent of participants were women.
Over a period of 19 years, the researchers found that migraine was positively associated with heart attack, stroke, blood clots and irregular heart rate.
For example, for every 1,000 patients, 25 patients with migraine had a heart attack compared with 17 migraine free patients and 45 patients with migraine had an ischaemic stroke (blood clot in the brain) compared with 25 migraine free patients.
The associations, particularly for stroke, were stronger in the first year of diagnosis than the long term, in patients with migraine aura (warning signs before a migraine, such as seeing flashing lights) than in those without aura, and in women than in men. researchers said.
This is an observational study, so no firm conclusions can be drawn about cause and effect, and the researchers cannot rule out the possibility that other unknown factors, such as physical activity, may have influenced the results.
The researchers outline reasons why migraine might increase cardiovascular disease risk.
For example, people with migraine often use anti- inflammatory drugs, which are associated with increased risks of heart problems, while immobilisation related to migraine attacks may increase the risk of blood clots.
They note that current guidelines do not recommend use of anti-clotting drugs such as aspirin to treat migraine, but call on clinicians to "consider whether patients at particularly high risk of heart disease would benefit from anticoagulant treatment".
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
